David A. Siegel Alnylam Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 189,600 shares of ALNY stock, worth $46.1 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

189,600

Holding current value

$46.1 Million

% of portfolio

0.07%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $27.8 Million - $37.6 Million	189,600 New	189,600 $28.3 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $26.9 Million - $33.4 Million	-157,700 Reduced 81.46%	35,900 $6.36 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $7.12 Million - $8.16 Million	38,500 Added 24.82%	193,600 $36.8 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $6.41 Million - $8.27 Million	35,100 Added 29.25%	155,100 $31.1 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $10.4 Million - $13.6 Million	56,200 Added 88.09%	120,000 $28.5 Million

Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $7.12 Million - $11.9 Million	51,400 Added 414.52%	63,800 $12.8 Million
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $4.13 Million - $5.81 Million	-34,300 Reduced 73.45%	12,400 $1.81 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $5.46 Million - $7.46 Million	42,900 Added 1128.95%	46,700 $7.63 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $606,328 - $795,302	3,800 New	3,800 $644,000
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $4.1 Million - $5.64 Million	-31,900 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $3.58 Million - $4.95 Million	28,200 Added 762.16%	31,900 $4.5 Million
Q4 2020 Feb 16, 2021	BUY	$122.97 - $147.0 $454,989 - $543,900	3,700 New	3,700 $481,000
Q3 2020 Nov 16, 2020	SELL	$121.19 - $165.49 $1.01 Million - $1.37 Million	-8,300 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $864,943 - $1.3 Million	8,300 New	8,300 $1.23 Million
Q2 2019 Aug 14, 2019	SELL	$65.86 - $92.79 $4.66 Million - $6.57 Million	-70,800 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $3.37 Million - $4.33 Million	-46,300 Reduced 39.54%	70,800 $6.62 Million
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $4.54 Million - $6.4 Million	-72,400 Reduced 38.21%	117,100 $8.54 Million
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $3.88 Million - $5.44 Million	-44,322 Reduced 18.96%	189,500 $16.6 Million
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $10.9 Million - $13.3 Million	-123,400 Reduced 34.54%	233,822 $23 Million
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $28.8 Million - $36.9 Million	248,200 Added 227.66%	357,222 $42.5 Million
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $12.5 Million - $15.3 Million	109,022	109,022 $13.9 Million

Others Institutions Holding ALNY

# of Institutions

584

Shares Held

104M

Call Options Held

2.82M

Put Options Held

1.75M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.9B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account